Literature DB >> 19010400

The detection and measurement of locomotor deficits in a transgenic mouse model of Huntington's disease are task- and protocol-dependent: influence of non-motor factors on locomotor function.

Patrick N Pallier1, Cheney J G Drew, A Jennifer Morton.   

Abstract

Locomotor performance of transgenic R6/2 mice carrying the Huntington's disease (HD) mutation was assessed using four different tasks, fixed speed rotarod, accelerating rotarod, Digigait and footprint test. The tasks were compared directly in age- and CAG repeat-matched R6/2 mice. Accelerating rotarod was more sensitive than fixed speed rotarod for detecting early motor deficits in R6/2 mice. The sensitivity of accelerating rotarod increased with the acceleration rate and/or the start speed from which the rod accelerated. Differences between tasks were not due to inability of R6/2 mice to maintain balance at high speeds or increased fatigue on accelerating rotarod, but to difficulties in coordinating gait changes required by the constant change in speed on accelerating rotarod. The footprint test was sensitive to gait disturbances. However, surprisingly, R6/2 mice did not show major gait abnormalities on an automated treadmill task (Digigait), even though they showed overt gait deficits in the home cage. The fact that the sensitivity for detecting motor deficits depended strongly on the individual task, and on the protocol used, suggests that non-motor factors were differentially engaged in the different paradigms. We thus recommend that more than one task should be used for detecting and tracking different aspects of motor decay in animal models of HD. Since deficits in non-motor factors such as executive function and motivation may differentially influence motor outcome in each task, our results call for a more thorough investigation of the importance of higher level control of locomotion in animal models of HD.

Entities:  

Mesh:

Year:  2008        PMID: 19010400     DOI: 10.1016/j.brainresbull.2008.10.007

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  26 in total

1.  Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease.

Authors:  Lori Zacharoff; Ivan Tkac; Qingfeng Song; Chuanning Tang; Patrick J Bolan; Silvia Mangia; Pierre-Gilles Henry; Tongbin Li; Janet M Dubinsky
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-02       Impact factor: 6.200

2.  SCA1-like disease in mice expressing wild-type ataxin-1 with a serine to aspartic acid replacement at residue 776.

Authors:  Lisa Duvick; Justin Barnes; Blake Ebner; Smita Agrawal; Michael Andresen; Janghoo Lim; Glenn J Giesler; Huda Y Zoghbi; Harry T Orr
Journal:  Neuron       Date:  2010-09-23       Impact factor: 17.173

3.  Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice.

Authors:  Danielle A Simmons; Rishi A Mehta; Julie C Lauterborn; Christine M Gall; Gary Lynch
Journal:  Neurobiol Dis       Date:  2010-10-23       Impact factor: 5.996

4.  Adenoviral astrocyte-specific expression of BDNF in the striata of mice transgenic for Huntington's disease delays the onset of the motor phenotype.

Authors:  Leticia Arregui; Jorge A Benítez; Luis F Razgado; Paula Vergara; Jose Segovia
Journal:  Cell Mol Neurobiol       Date:  2011-06-17       Impact factor: 5.046

Review 5.  Choosing an animal model for the study of Huntington's disease.

Authors:  Mahmoud A Pouladi; A Jennifer Morton; Michael R Hayden
Journal:  Nat Rev Neurosci       Date:  2013-10       Impact factor: 34.870

6.  ER Stress Induced by Tunicamycin Triggers α-Synuclein Oligomerization, Dopaminergic Neurons Death and Locomotor Impairment: a New Model of Parkinson's Disease.

Authors:  Valentín Cóppola-Segovia; Clarissa Cavarsan; Flavia G Maia; Anete C Ferraz; Lia S Nakao; Marcelo Ms Lima; Silvio M Zanata
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

7.  Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline.

Authors:  Liliana B Menalled; Monica Patry; Natalie Ragland; Phillip A S Lowden; Jennifer Goodman; Jennie Minnich; Benjamin Zahasky; Larry Park; Janet Leeds; David Howland; Ethan Signer; Allan J Tobin; Daniela Brunner
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

8.  Use of a force-sensing automated open field apparatus in a longitudinal study of multiple behavioral deficits in CAG140 Huntington's disease model mice.

Authors:  Stephen C Fowler; Nancy A Muma
Journal:  Behav Brain Res       Date:  2015-07-22       Impact factor: 3.332

9.  Neurological Dysfunction in Early Maturity of a Model for Niemann-Pick C1 Carrier Status.

Authors:  Ya Hui Hung; Mark Walterfang; Leonid Churilov; Lisa Bray; Laura H Jacobson; Kevin J Barnham; Nigel C Jones; Terence J O'Brien; Dennis Velakoulis; Ashley I Bush
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

10.  Response to ethanol induced ataxia between C57BL/6J and 129X1/SvJ mouse strains using a treadmill based assay.

Authors:  Stephen T Hansen; Stefan M Pulst
Journal:  Pharmacol Biochem Behav       Date:  2012-10-24       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.